<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://akltherapeutics.com/wp-sitemap.xsl" ?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"><url><loc>https://akltherapeutics.com/akl-has-completed-required-appa-preclinical-toxicology-studies-successfully/</loc><lastmod>2021-02-05T10:22:34+00:00</lastmod></url><url><loc>https://akltherapeutics.com/common-painkillers-also-linked-to-increased-risk-of-heart-failure-bmj-finds/</loc><lastmod>2020-11-24T16:20:02+00:00</lastmod></url><url><loc>https://akltherapeutics.com/paracetamol-useless-in-treating-osteoarthritis-pain/</loc><lastmod>2025-01-21T12:38:28+00:00</lastmod></url><url><loc>https://akltherapeutics.com/new-family-link-to-osteoarthritis/</loc><lastmod>2020-11-24T16:15:47+00:00</lastmod></url><url><loc>https://akltherapeutics.com/summary-effects-appa-neutrophils/</loc><lastmod>2023-02-03T08:56:51+00:00</lastmod></url><url><loc>https://akltherapeutics.com/liverpool-university-press-release/</loc><lastmod>2021-02-05T10:24:27+00:00</lastmod></url><url><loc>https://akltherapeutics.com/akl-appa-press/</loc><lastmod>2025-01-21T12:26:42+00:00</lastmod></url><url><loc>https://akltherapeutics.com/exploited-plants-offer-untold-medical-economic-promise/</loc><lastmod>2023-02-03T08:55:06+00:00</lastmod></url><url><loc>https://akltherapeutics.com/mhra-approval-for-formal-human-trials-to-start/</loc><lastmod>2023-01-23T10:52:08+00:00</lastmod></url><url><loc>https://akltherapeutics.com/phase-i-clinical-trial-at-the-university-of-liverpool/</loc><lastmod>2023-01-23T10:51:40+00:00</lastmod></url><url><loc>https://akltherapeutics.com/more-weight-loss-tied-to-less-knee-pain-for-obese-people/</loc><lastmod>2023-02-03T08:54:11+00:00</lastmod></url><url><loc>https://akltherapeutics.com/aklrd-and-nordic-bioscience-announce-collaboration/</loc><lastmod>2023-01-23T10:50:29+00:00</lastmod></url><url><loc>https://akltherapeutics.com/an-important-milestone-in-the-development-of-appa/</loc><lastmod>2021-02-05T10:28:40+00:00</lastmod></url><url><loc>https://akltherapeutics.com/former-investment-banker-appointed-cfo-of-akl/</loc><lastmod>2023-01-23T10:49:59+00:00</lastmod></url><url><loc>https://akltherapeutics.com/new-evidence-on-the-mode-of-action-of-appa/</loc><lastmod>2023-02-03T08:50:43+00:00</lastmod></url><url><loc>https://akltherapeutics.com/positive-result-in-appa-phase-i-clinical-trial/</loc><lastmod>2023-01-23T10:49:20+00:00</lastmod></url><url><loc>https://akltherapeutics.com/new-research-published-on-appas-mode-of-action/</loc><lastmod>2020-11-06T16:47:47+00:00</lastmod></url><url><loc>https://akltherapeutics.com/abstract-published-at-eular-2020/</loc><lastmod>2021-06-21T08:43:49+00:00</lastmod></url><url><loc>https://akltherapeutics.com/how-close-are-disease%e2%80%90modifying-drugs-for-osteoarthritis/</loc><lastmod>2023-02-03T08:43:40+00:00</lastmod></url><url><loc>https://akltherapeutics.com/personalised-medicine-disease-modification-in-oa/</loc><lastmod>2021-04-19T13:26:20+00:00</lastmod></url><url><loc>https://akltherapeutics.com/appa-phase-ii-human-efficacy-study-completes-patient-recruitment-a-month-ahead-of-schedule/</loc><lastmod>2023-01-23T10:46:27+00:00</lastmod></url><url><loc>https://akltherapeutics.com/new-studies-suggests-appa-protects-against-joint-damage/</loc><lastmod>2021-04-28T17:27:05+00:00</lastmod></url><url><loc>https://akltherapeutics.com/appa-reduces-senescence-reactive-oxygen-species-production/</loc><lastmod>2023-02-03T08:42:15+00:00</lastmod></url><url><loc>https://akltherapeutics.com/appa-granted-innovation-passport-by-mhra/</loc><lastmod>2023-01-23T10:45:58+00:00</lastmod></url><url><loc>https://akltherapeutics.com/completion-of-phase-2a-human-trial/</loc><lastmod>2025-04-25T08:06:38+00:00</lastmod></url><url><loc>https://akltherapeutics.com/senescence-research-in-appa-with-inibic/</loc><lastmod>2023-01-23T10:41:42+00:00</lastmod></url><url><loc>https://akltherapeutics.com/eular-oarsi-2022-presentations/</loc><lastmod>2023-02-20T10:21:03+00:00</lastmod></url><url><loc>https://akltherapeutics.com/oarsi-2023-presentation/</loc><lastmod>2023-03-20T15:46:24+00:00</lastmod></url><url><loc>https://akltherapeutics.com/new-senomorphic-patent-filed/</loc><lastmod>2022-12-14T16:13:25+00:00</lastmod></url><url><loc>https://akltherapeutics.com/phase-ii-osteoarthritis-clinical-trial-underway/</loc><lastmod>2023-02-13T18:43:53+00:00</lastmod></url><url><loc>https://akltherapeutics.com/akl-therapeutics-combines-synthesized-plant-metabolites-to-create-promising-oral-oa-treatment/</loc><lastmod>2023-03-22T12:02:43+00:00</lastmod></url><url><loc>https://akltherapeutics.com/appa-shows-promise-in-age-related-diseases/</loc><lastmod>2024-01-17T11:30:41+00:00</lastmod></url><url><loc>https://akltherapeutics.com/anti-inflammatory-activity-of-appa-in-human-chondrocytes/</loc><lastmod>2025-09-16T17:51:07+00:00</lastmod></url><url><loc>https://akltherapeutics.com/appa-phase-2a-results-published-in-osteoarthritis-cartilage/</loc><lastmod>2024-05-08T07:51:51+00:00</lastmod></url><url><loc>https://akltherapeutics.com/appa-phase-2b-clinical-trial-ahead-of-schedule/</loc><lastmod>2025-04-24T15:01:04+00:00</lastmod></url><url><loc>https://akltherapeutics.com/senotherapeutic-effects-of-appa-on-senescent-human-chondrocytes/</loc><lastmod>2025-09-16T18:03:44+00:00</lastmod></url><url><loc>https://akltherapeutics.com/dr-nicholas-larkins-bvsc-dsc-mrcvs/</loc><lastmod>2026-02-05T14:14:05+00:00</lastmod></url><url><loc>https://akltherapeutics.com/p2b-dose-ranging-study/</loc><lastmod>2026-03-18T09:06:10+00:00</lastmod></url><url><loc>https://akltherapeutics.com/oarsi-2026-late-breaking-abstract/</loc><lastmod>2026-04-23T18:38:56+00:00</lastmod></url><url><loc>https://akltherapeutics.com/acr-convergence-2026-abstract/</loc><lastmod>2026-11-09T15:00:01+00:00</lastmod></url></urlset>
